OpenLobby.EU
Explore

Medtronic

Medtronic

To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health, and extend life

Lobbying Activity

Meeting with Lauro Panella (Cabinet of Commissioner Maria Luís Albuquerque)

24 Nov 2025 · OECD’s Pillar Two tax framework Minimum Tax Directive

Meeting with Michalis Hadjipantela (Member of the European Parliament)

19 Nov 2025 · OECD Pillar Two

Meeting with Gabriela Tschirkova (Cabinet of Commissioner Valdis Dombrovskis)

7 Nov 2025 · OECD Pillar 2 tax framework

Meeting with Chiara Galiffa (Cabinet of Commissioner Maroš Šefčovič) and MedTech Europe and

25 Sept 2025 · EU – US relations

Meeting with Victor Negrescu (Member of the European Parliament) and FTI Consulting Belgium and

23 Sept 2025 · Meeting with MedTech Europe Cardiovascular Sector Group

Response to EU cardiovascular health plan

15 Sept 2025

Medtronic, as a global leader in medical technology and an innovator in cardiovascular care, welcomes the opportunity to contribute to the EU Cardiovascular Health Plan. We strongly support the European Commissions ambition to address the growing burden of cardiovascular disease (CVD) in Europe and believe that the Plan can drive measurable improvements in prevention, detection, and treatment improving public health and contributing to competitiveness and innovation. We particularly welcome the recognition of high blood pressure as a key risk factor for CVD. Hypertension is the leading preventable cause of cardiovascular morbidity and mortality worldwide. Yet research shows large variation in control. Beyond the human toll, uncontrolled hypertension represents a significant cost to health systems due to avoidable hospitalisations and long-term complications. We therefore urge the European Commission to integrate clear measures on hypertension control in the Plan. We also welcome the Commissions acknowledgement that cardiovascular disease is too often perceived as a mens issue. Women continue to face systemic inequities across the cardiovascular spectrum: late diagnosis, misattribution of symptoms, and inequitable access to treatment. Pelvic Venous Disorders (PeVD) illustrate this inequity. Women can suffer from PeVD, an important cause of chronic pelvic pain, for years without diagnosis due to non-specific symptoms, stigma and lack of awareness. Addressing this hidden burden requires targeted attention in the EU Plan. Similarly, Heart Valve Disease (HVD), although increasingly recognised as the next cardiac epidemic, remains under-recognised, under-diagnosed, and under-treated, particularly among women. Simple assessments such as stethoscope checks are often missed, while symptoms are dismissed or misattributed. HVD can progress to Heart Failure (HF), where gender disparities are significant: women wait on average six times longer than men for a diagnosis. Such delays can have serious and irreversible consequences. Other key examples where gender inequities occur are Atrial Fibrillation (AF) and stroke. Women experience a faster increase in AF burden, including an increased risk of stroke, and face challenges in access to treatment and care. The EU CVH Plan represents a unique opportunity to address these challenges through coordinated European action. We call upon the European Commission to consider the following recommendations: 1) Establish a European Cardiovascular Health Check Programme, including targeted screening through gender-sensitive approaches. Solutions such as digital stethoscopes and connected blood pressure monitors, can play a vital role in enabling timely detection and intervention. 2) Support early detection with clear referral and treatment pathways across Member States, backed by EU-level guidance, to ensure that patients move seamlessly from screening to diagnosis and effective treatment, optimising outcomes for patients and healthcare systems. 3) Strengthen care delivery through an EU Network of Centres of Excellence to improve patient care, foster research and innovation efforts. 4) Invest in evidence-based decision-making by enabling the deployment of registries. 5) Accelerate access to innovation by strengthening regulatory pathways, procurement, funding, and reimbursement mechanisms. We strongly support the Commissions vision for a comprehensive, equitable approach to cardiovascular health. By addressing hypertension control, embedding gender-sensitive detection and follow-up, and ensuring access to innovative solutions, the EU Cardiovascular Health Plan can deliver transformative impact.
Read full response

Meeting with Lucilla Sioli (Director Communications Networks, Content and Technology) and

27 Aug 2025 · Exchange of views on AI in medical devices and AI Act implementation

Meeting with Katarina Koszeghy (Cabinet of Commissioner Wopke Hoekstra), Bernardus Zuijdendorp (Head of Unit Taxation and Customs Union)

19 Aug 2025 · Exchange of views on Pillar Two (Global Minimum Tax)

Response to EU Life sciences strategy

17 Apr 2025

Medtronic believes that the EU life sciences strategy represents a pivotal moment for European healthcare and healthcare delivery. Providing the timely opportunity and policy to intelligently help transform Europes healthcare and health delivery models to be a force for health, growth and jobs. The EU life science strategy could foster and be a platform for the needed partnerships to address healthcare systems needs and trends, ensure equitable, timely, and affordable patient access to care, while fostering a resilient and innovative medical technology ecosystem, driving progress and contributing to European competitiveness. Championing universal healthcare, tackling health inequalities and fostering breakthrough therapy innovation in medical technology, Europe has long been a leader in advanced care and innovation in healthcare and healthcare delivery. That crown may be tilting. Without transformation, healthcare systems, and the eco-system that supports them, risk not being fit-for-purpose for whats ahead. We are in an increasingly complex world, with many complex challenges facing governments, health ministers, hospital administrations, physicians and carers. Geopolitical tensions, post-covid inflation, financial sustainability, economic pressure, workforce challenges, staff well-being, stagnating innovation and staying competitive, to name but a few. These challenges are further compounded by the persistent structural fragmentation of healthcare delivery with siloed operations, duplication of effort, and limited scalability as well as fragmented digital infrastructure, evolving skills needs, and regulatory complexity that slows innovation and adoption. Medtronic is optimistic. These challenges provide an opportunity to do better than before. If we continue to try to solve the same things in the same way, in the same siloes, we will only end up in the same spot. If we embrace the opportunity, and have a more collaborative and systemic approach, breaking down traditional siloes, while also advancing the safe and responsible use of data, artificial intelligence and interoperable infrastructure, we can address the fragmentation that the challenges create, support skills development, and accelerate the adoption of scalable, resilient, patient-centered solutions. It is a powerful ecosystem: patients, government, ministries of finance, health, research and economy, physicians, nurses, carers, academia, industry, medtech innovation hubs, payers, insurers and the investment community. Industry, in particular, stands ready to co-create this transformation not only through innovation, but by contributing operational know-how, data-driven insights, and scalable models that support the reinvention of care delivery. Furthermore, industry can add resources to echo and uplift the commitment to public health, and the EU life sciences strategy, through education and public awareness campaigns, and digital communication tools to improve patient experiences and to help people manage and prevent health issues. The EU life sciences strategy could create the needed platforms and streamline pathways to foster the partnerships to enable this powerful ecosystem. Working together as a health community, co-investing in emerging research areas and innovation, fostering knowledge exchange, and driving change consistently within our respective specialties, while collaborating across the ecosystem, and aligning technological advancements with societal values, can ensure we drive progress and contribute to European competitiveness. Medtronic looks forward to actively contributing to the strategy in action. About us: Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission is to alleviate pain, restore health, and extend life.
Read full response

Response to Evaluation of the Public Procurement Directives

7 Mar 2025

Medtronic contribution to EU Public Procurement consultation on the evaluation of the EUs Public Procurement Directives (Directive 2014/23/EU on the award of concession contracts Directive 2014/24/EU on public procurement) Medtronic is a global leader in medical technology, services, and solutions. More than 70 conditions in the human body are treated with our therapies. General Recommendations: Effectively lowering total healthcare spend (e.g. by taking advantage of economies of scale and paving the ground for financial predictability); maximizing patient access (to new and safe technology); ensuring competition and access to Public Contracts; and promotion of administrative efficiency are all key objectives for public procurement within the healthcare sector but it is also important to underline the constant need for process transparency (to reduce any corruption risks) aligned with standardization of processes to reduce red tape. As economic operator, Medtronic emphasizes the importance to potentiate the mechanism in the concession contracts and in the public procurement framework for the award of services solutions and technologies that prove the Value for Money for public administrations operating in the strategic and sensitive sector (i.e. Healthcare) through a Value Based procurement approach as a tool for evaluating technologies and solutions in the public procurement process. Public procurement legal framework and practice should focus on ensuring Value for Money i.e. proportional, effective and efficient use of resources considering the entire procurement cycle based on the desired clinical, economic, and social outcomes. In the realm of medical technology, that means improved outcomes, expanded access and optimization of costs and efficiencies. The suggested framework is based on the principle to achieve sustainability while ensuring the most efficient use of public funds in force of the tools that allow to demonstrate capabilities to deliver the expected outcome or performance improving in a perspective of public administration. Furthermore, should be made clear in the public procurement legislation the mechanisms through which public administrations can incentivize, after the contract signature, the economic operators that improve quality of services delivered. Feedback on specific articles of the directive 2014/24/EU As per above mentioned principles the following suggestions should be made: It would be desirable for Articles 67 (Contract award criteria), 68 (Life-cycle costing) and 70 (Conditions for performance of contracts) of Directive 2014/24/EU to explicitly include in the award criteria the principle of value-based procurement. Award Criteria: o Article 67 sub-paragraph 1 reports contracting authorities shall base the award of public contracts on the most economically advantageous tender (MEAT)- we suggest giving more details/ guidelines for the interpretation of most economic advantageous criteria to avoid discretionally interpretation of this criteria o Avoid the lowest-price criteria for services and solutions based on contracts that prove performance and or specific outcome for public administration. o Introduce mechanism that allow the measure of quality (as per value-based procurement principle) to increase level of transparency and measurability of procurement o Promote procurement systems that reinforce MEAT criteria in a consistent framework that allow cost- effectiveness and innovation recognitions such as outcome-based procurement and incentive contracting in performance-based procurement.
Read full response

Meeting with Barry Cowen (Member of the European Parliament)

17 Oct 2024 · Medtronic Meeting

Response to Health technology assessment – Procedural rules for the assessment and management of conflicts of interest in joint wo

26 Jun 2024

Medtronic is pleased to be able to contribute to the implementation of the European HTA Regulation (HTAR), working towards a regulation that is fit-for-purpose and improves the availability and funding of innovative health care technologies. We welcome the opportunity to provide feedback on this draft implementing act on the management of conflict of interest in the context of joint work (CoI IA). Medtronic supports the goals of the Commission and is committed to the management of conflicts of interest under the HTAR. We believe, however, that it is important to strike the right balance between impartiality, transparency, and involving the most qualified experts in the HTA processes, in particular with respect to Joint Clinical Assessments (JCAs). We are concerned that as written, the proposed implementing act will inadvertently exclude key experts from being able to participate in the assessments, thereby potentially impacting quality and usability of the HTAs conducted. In attached document, we summarise our key concerns and questions related to this draft implementing act. We believe that addressing these would contribute to the relevance and quality of JCAs under the HTAR, while maintaining the independence and impartiality of EU level JCAs. Our comments fall into three main areas: - Importance of clinical expertise in the area of innovative medical devices - Proposal for conflicts of interest management rather than full exclusion - Requests for more clarity on specific elements of the implementing act
Read full response

Meeting with Patricia Reilly (Cabinet of Commissioner Mairead Mcguinness)

6 Dec 2023 · different implementation timelines of the globally agreed OECD minimum tax rate

Meeting with Mairead McGuinness (Commissioner) and

3 Dec 2021 · Medtronic’s work during the COVID pandemic re supply of ventilators; company’s latest work in developing innovative medical devices; sustainability

Response to Requirements for Artificial Intelligence

6 Aug 2021

Please find our feedback attached.
Read full response

Meeting with Ursula von der Leyen (President) and

25 Mar 2020 · Videoconference with CEOs on COVID-19